fluorouracil has been researched along with shogaol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, S; Makuch, S; Winograd, K; Wiśniewski, J; Woźniak, M; Ziółkowski, P | 1 |
| Chen, YZ; Qu, Y; Zhang, Y | 1 |
2 other study(ies) available for fluorouracil and shogaol
| Article | Year |
|---|---|
6-Shogaol enhances the anticancer effect of 5-fluorouracil, oxaliplatin, and irinotecan via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Catechols; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Immunosuppressive Agents; Irinotecan; Oxaliplatin; Topoisomerase I Inhibitors | 2020 |
Influence of 6-shogaol potentiated on 5-fluorouracil treatment of liver cancer by promoting apoptosis and cell cycle arrest by regulating AKT/mTOR/MRP1 signalling.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Catechols; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2022 |